Contact Us
  • Choose License Type

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,168.4 million in 2020 and is estimated to exhibit a CAGR of 4.5% during the forecast period (2020-2027).

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID–19 pandemic is expected to restrain the global chemotherapy-induced thrombocytopenia therapeutics market growth during the forecast period. The number of COVID-19 cases are increasing at an exponential rate, globally. For instance, according to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 62,844,837 cases and 1,465,144 million deaths due to coronavirus disease (COVID-19) were reported on December 01, 2020, across the globe.

The shutdown has disrupted the supply, distribution, and manufacture of medical supplies globally. Moreover, owing to social distancing, the footfall in clinics and health institutions has fallen by more than 70% during this pandemic, which has led to decrease in number of surgical procedures, which has negatively impacted the market growth.

The COVID-19 pandemic has affected the economy in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets.

Rising cancer cases is expected to drive the demand for chemotherapy procedures and thereby and thereby expected to drive the market growth in the near future. For instance, according to the American Cancer Society April 2020, around 178,520 people in the U.S. are estimated to be diagnosed with leukemia, lymphoma or myeloma in 2020. Moreover, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.

The increasing incidence of chemotherapy-induced thrombocytopenia is also the major factor that is expected to fuel the market growth over the forecast period. For instance, according to the article published in the BMC Cancer, a medical Journal in February 2019, the below mentioned table provides information about incidence of chemotherapy-induced thrombocytopenia, caused by the chemotherapy agents in the U.S. during the period of 2010 to 2016.

Chemotherapy Agent All Agents Carboplatin Cisplatin Chemotherapy Agent Cyclophosphamide Fluorouracil Gemcitabine Oxaliplatin
Number of Patients 215,508 60,966 22,393 83,665 42,970 6617 33,822 14,610
Overall Incidence 9.7 13.2 9.9 6.1 10.9 13.5 11.4 9.6
Inpatient Incidence 3.0 4.2 4.3 1.6 3.0 5.5 2.9 3.5
Outpatient Incidence 6.7 9.0 9.0 4.5 4.5 4.5 8.5 6.1

Browse 29  Market Data Tables and 21 Figures spread through 148 Pages and in-depth TOC on Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), by Route of Administration (Oral and Injectables), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)  - Global Forecast to 2027

To know the latest trends and insights prevalent in the Chemotherapy-induced Thrombocytopenia Therapeutics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/chemotherapy-induced-thrombocytopenia-therapeutics-market-4332

Rising number of research and development activities by the market players and research organizations, in order to provide novel therapeutics for the treatment of chemotherapy-induced thrombocytopenia is expected to drive growth of market during the forecast period. For instance, on 19th October 2020, Institute of Hematology & Blood Diseases Hospital initiated the single-arm study to evaluate the safety and efficacy of eltrombopag to treat chemotherapy-induced thrombocytopenia. The study is under Phase II trial and is expected to complete by December 2023.

Key Takeaways of the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market:

  • The global chemotherapy-induced thrombocytopenia therapeutics market is expected to exhibit a CAGR of 4.5% during the forecast period (2020–2027), owing to rising number of cancer cases and adoption of chemotherapy. For instance, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. According to the same source, the number of people with cancer is expected to rise and reach 19 million by 2024.
  • Some of the major players operating in the chemotherapy-induced thrombocytopenia therapeutics market include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum)
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner